Gainers
- Theravance Biopharma (NASDAQ:TBPH) shares moved upwards by 29.8% to $11.2 during Wednesday's after-market session. At the close, Theravance Biopharma's trading volume reached 848.9K shares. This is 169.7% of its average volume over the last 100 days. The company's market cap stands at $852.4 million.
- Innoviva (NASDAQ:INVA) stock moved upwards by 10.67% to $15.45. The company's market cap stands at $1.0 billion.
- Artelo Biosciences (NASDAQ:ARTL) stock increased by 8.65% to $0.36. The market value of their outstanding shares is at $15.5 million.
- ThermoGenesis Holdings (NASDAQ:THMO) stock increased by 7.99% to $0.22. The market value of their outstanding shares is at $2.7 million.
- aTyr Pharma (NASDAQ:LIFE) shares moved upwards by 7.41% to $3.33. The company's market cap stands at $93.4 million.
- Calithera Biosciences (NASDAQ:CALA) shares moved upwards by 7.4% to $2.9. The company's market cap stands at $14.0 million.
Losers
- ContraFect (NASDAQ:CFRX) stock declined by 77.1% to $0.65 during Wednesday's after-market session. ContraFect's trading volume hit 3.0 million shares by close, accounting for 1922.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $25.6 million.
- Azenta (NASDAQ:AZTA) stock decreased by 11.01% to $66.0. The market value of their outstanding shares is at $4.9 billion.
- Marker Therapeutics (NASDAQ:MRKR) shares fell 7.2% to $0.32. The market value of their outstanding shares is at $26.7 million.
- NeuroMetrix (NASDAQ:NURO) stock fell 6.32% to $3.41. The company's market cap stands at $24.3 million.
- Kiromic BioPharma (NASDAQ:KRBP) shares decreased by 6.31% to $0.44. The market value of their outstanding shares is at $6.9 million.
- SELLAS Life Sciences Gr (NASDAQ:SLS) shares declined by 6.26% to $2.4. The company's market cap stands at $49.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.